| Market Capitalization (Millions $) |
3,966 |
| Shares
Outstanding (Millions) |
174 |
| Employees |
207 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-465 |
| Cash Flow (TTM) (Millions $) |
49 |
| Capital Exp. (TTM) (Millions $) |
0 |
Immunovant Inc
Immunovant Inc is a biopharmaceutical company that focuses on developing novel therapies for autoimmune diseases. The company utilizes a proprietary technology platform to develop small molecules and monoclonal antibodies that target specific components of the immune system to modulate immune responses.
Immunovant's lead candidate, IMVT-1401, is an investigational anti-FcRn antibody being developed for the treatment of autoimmune diseases, including myasthenia gravis and pemphigus vulgaris. FcRn is a protein that plays a role in the recycling of immunoglobulins, and by inhibiting its function, IMVT-1401 aims to reduce the levels of pathogenic antibodies that contribute to autoimmune disease.
The company's research and development efforts are driven by a team of experienced scientists and clinicians with expertise in immunology and autoimmune diseases. Immunovant is committed to advancing its pipeline of innovative therapies to address the unmet medical needs of patients with autoimmune disorders.
Immunovant Inc was previously a subsidiary of Roivant Sciences but became an independent publicly traded company in October 2019. The company is headquartered in New York, United States.
Company Address: 320 West 37th Street New York, 10018 NY
Company Phone Number: 580-3099 Stock Exchange / Ticker: NASDAQ IMVT
|
7.09%